Attovia Therapeutics, Inc. (NASDAQ:ATTO) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesMarket Beat·Sep 9 at 12:14 PMATTO-11.09%
Attovia Therapeutics, Inc.'s (NASDAQ:ATTO) Quiet Period To End on September 14thMarket Beat·Sep 7 at 05:20 AMATTO-11.09%GS-1.38%
Biotech Stocks At 52-Week Highs - ATTO, HALO, IKT, TVTX, ATRCrttnews·Sep 4 at 09:20 AMATTO-11.09%TVTX-0.75%
Attovia Therapeutics to Participate in Upcoming Investor ConferencesUnusual Whales·Sep 3 at 08:07 PMATTO-11.09%
Attovia's Q2 Loss Expands With Increased Trials For ATTO-1310; Plans Phase 2 For Q1 '27rttnews·Sep 3 at 04:50 PMATTO-11.09%
Sam Slutsky Reiterates Buy on Attovia, Maintains $45 Price Target on Strong Early ATTO-1310 Data and Robust Cash RunwayTip Ranks·Sep 3 at 03:55 PMATTO-11.09%
Attovia Therapeutics, Inc. GAAP EPS of -$4.88 misses by $4.25, revenue of $0.45Mbusinessinsider·Sep 2 at 08:31 PMATTO-11.09%
ATTO: Lead program shows clinical proof of concept; IPO funds extend cash runway into 2030Quartr·Sep 2 at 08:24 PMATTO-11.09%
Attovia Q2 FY26 net loss widens to $20.7 million; revenue rises to $0.5 millionPUBT·Sep 2 at 08:18 PMATTO-11.09%
Attovia Therapeutics (NASDAQ:ATTO) Upgraded by Royal Bank Of Canada to "Moderate Buy" RatingMarket Beat·Sep 1 at 10:30 AMATTO-11.09%
Morgan Stanley Begins Coverage on Attovia Therapeutics (NASDAQ:ATTO)Market Beat·Aug 31 at 12:06 PMATTO-11.09%BLK-0.54%
